Table 4.

Clinical outcome on erlotinib therapy according to the preerlotinib IRS for p21waf in the basal-like cell layer, using 3 as a cutoff

p21waf IRS
Total
0-34-12
No. patients with progression or stable disease18422
No. patients with tumor response099
Total181331